Literature DB >> 20824400

Hemorrhagic colonic ulcers caused by dasatinib for chronic myelogenous leukemia.

Yukako Ono, Takehiko Mori, Jun Kato, Akiko Yamane, Tomoharu Yajima, Yasushi Iwao, Toshifumi Hibi, Shinichiro Okamoto.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 20824400     DOI： 10.1007/s12185-010-0677-7

Source DB:  PubMed          Journal:  Int J Hematol        ISSN： 0925-5710            Impact factor:   2.490


× No keyword cloud information.
  15 in total

1.  Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias.

Authors:  Moshe Talpaz; Neil P Shah; Hagop Kantarjian; Nicholas Donato; John Nicoll; Ron Paquette; Jorge Cortes; Susan O'Brien; Claude Nicaise; Eric Bleickardt; M Anne Blackwood-Chirchir; Vishwanath Iyer; Tai-Tsang Chen; Fei Huang; Arthur P Decillis; Charles L Sawyers
Journal:  N Engl J Med       Date:  2006-06-15       Impact factor: 91.245

2.  Pericyte loss and microaneurysm formation in PDGF-B-deficient mice.

Authors:  P Lindahl; B R Johansson; P Levéen; C Betsholtz
Journal:  Science       Date:  1997-07-11       Impact factor: 47.728

3.  Dasatinib induces complete hematologic and cytogenetic responses in patients with imatinib-resistant or -intolerant chronic myeloid leukemia in blast crisis.

Authors:  Jorge Cortes; Philippe Rousselot; Dong-Wook Kim; Ellen Ritchie; Nelson Hamerschlak; Steven Coutre; Andreas Hochhaus; Francois Guilhot; Giuseppe Saglio; Jane Apperley; Oliver Ottmann; Neil Shah; Philipp Erben; Susan Branford; Prasheen Agarwal; Ashwin Gollerkeri; Michele Baccarani
Journal:  Blood       Date:  2006-12-21       Impact factor: 22.113

4.  Clinical features of dasatinib-induced large granular lymphocytosis and pleural effusion.

Authors:  Yasunobu Nagata; Kazuteru Ohashi; Shiomi Fukuda; Noriko Kamata; Hideki Akiyama; Hisashi Sakamaki
Journal:  Int J Hematol       Date:  2010-04-20       Impact factor: 2.490

5.  Dasatinib induces notable hematologic and cytogenetic responses in chronic-phase chronic myeloid leukemia after failure of imatinib therapy.

Authors:  Andreas Hochhaus; Hagop M Kantarjian; Michele Baccarani; Jeffrey H Lipton; Jane F Apperley; Brian J Druker; Thierry Facon; Stuart L Goldberg; Francisco Cervantes; Dietger Niederwieser; Richard T Silver; Richard M Stone; Timothy P Hughes; Martin C Muller; Rana Ezzeddine; Athena M Countouriotis; Neil P Shah
Journal:  Blood       Date:  2006-11-30       Impact factor: 22.113

6.  Clonal expansion of T/NK-cells during tyrosine kinase inhibitor dasatinib therapy.

Authors:  S Mustjoki; M Ekblom; T P Arstila; I Dybedal; P K Epling-Burnette; F Guilhot; H Hjorth-Hansen; M Höglund; P Kovanen; T Laurinolli; J Liesveld; R Paquette; J Pinilla-Ibarz; A Rauhala; N Shah; B Simonsson; M Sinisalo; J L Steegmann; L Stenke; K Porkka
Journal:  Leukemia       Date:  2009-03-19       Impact factor: 11.528

7.  The new tyrosine-kinase inhibitor and anticancer drug dasatinib reversibly affects platelet activation in vitro and in vivo.

Authors:  Marie-Pierre Gratacap; Valérie Martin; Marie-Cécile Valéra; Sophie Allart; Cédric Garcia; Pierre Sié; Christian Recher; Bernard Payrastre
Journal:  Blood       Date:  2009-06-03       Impact factor: 22.113

Review 8.  Clinical profile of dasatinib in Asian and non-Asian patients with chronic myeloid leukemia.

Authors:  Dong-Wook Kim; Yeow-Tee Goh; Hui-Hua Hsiao; Priscilla B Caguioa; Dongho Kim; Wan-Seok Kim; Tapan Saikia; Shruti Agrawal; Amit Roy; David Dai; M Brigid Bradley-Garelik; Jaydip Mukhopadhyay; Saengsuree Jootar
Journal:  Int J Hematol       Date:  2009-05-20       Impact factor: 2.490

9.  Tyrosine kinase inhibitor-induced platelet dysfunction in patients with chronic myeloid leukemia.

Authors:  Alfonso Quintás-Cardama; Xin Han; Hagop Kantarjian; Jorge Cortes
Journal:  Blood       Date:  2009-05-04       Impact factor: 22.113

10.  Physical and functional association of the Src family kinases Fyn and Lyn with the collagen receptor glycoprotein VI-Fc receptor gamma chain complex on human platelets.

Authors:  Y Ezumi; K Shindoh; M Tsuji; H Takayama
Journal:  J Exp Med       Date:  1998-07-20       Impact factor: 14.307
View more
  5 in total

Review 1.  A narrative review on adverse effects of dasatinib with a focus on pharmacotherapy of dasatinib-induced pulmonary toxicities.

Authors:  Zahra Nekoukar; Minoo Moghimi; Ebrahim Salehifar
Journal:  Blood Res       Date:  2021-12-31

2.  Haemorrhagic colitis caused by dasatinib.

Authors:  Nishant Patodi; Nidhi Sagar; Zbigniew Rudzki; Gerald Langman; Naveen Sharma
Journal:  Case Rep Hematol       Date:  2012-12-22

3.  Dasatinib-induced hemorrhagic colitis complicated with cytomegalovirus infection.

Authors:  Aya Nakaya; Yoshiko Azuma; Shinya Fujita; Atsushi Satake; Takahisa Nakanishi; Yukie Tsubokura; Akiko Konishi; Masaaki Hotta; Hideaki Yoshimura; Kazuyoshi Ishii; Tomoki Ito; Shosaku Nomura
Journal:  Hematol Rep       Date:  2017-12-22

Review 4.  Successful treatment with allogeneic stem cell transplantation followed by DLI and TKIs for e6a2 BCR-ABL-positive acute myeloid leukaemia: A case report and literature review.

Authors:  Yasuhiko Harada; Satoshi Nishiwaki; Takumi Sugimoto; Koichi Onodera; Tatsunori Goto; Takahiko Sato; Sonoko Kamoshita; Naomi Kawashima; Aika Seto; Shingo Okuno; Satomi Yamamoto; Toshihiro Iwasaki; Yukiyasu Ozawa; Koichi Miyamura; Yoshiki Akatsuka; Isamu Sugiura
Journal:  Medicine (Baltimore)       Date:  2017-12       Impact factor: 1.817

5.  Varying effects of tyrosine kinase inhibitors on platelet function-A need for individualized CML treatment to minimize the risk for hemostatic and thrombotic complications?

Authors:  Suryyani Deb; Niklas Boknäs; Clara Sjöström; Anjana Tharmakulanathan; Kourosh Lotfi; Sofia Ramström
Journal:  Cancer Med       Date:  2019-11-12       Impact factor: 4.452
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.